Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Dennis Williams - SVP, Late Stage Development Gavin Wood - CFO John Lunger - VP, Manufacturing Conference Call Participants Marc Frahm - TD Cowen Jonathan Chang - SVB Leerink Arthur He - H.C. Wainwright Graig Suvannavejh - Mizuho Yanan Zhu - Wells Fargo Securities Operator Hello and welcome to Adaptimmune's First Quarter 2025 Business Update Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Officer Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development John Lunger - VP, Manufacturing and Supply Chain Conference Call Participants Jonathan Chang - Leerink Partners Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho George Farmer - Scotiabank Arthur He - H.C. Wainwright Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello, and welcome to the Adaptimmune's Q4 and Full Year 2024 Business Update Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development Conference Call Participants Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Paul Jeng - Guggenheim Yen-Der Li - Leerink Partners Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright George Farmer - Scotiabank Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello and welcome to the Adaptimmune Therapeutics Third Quarter 2024 Results Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Dan Od-Cohen - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Joanna Brewer - Chief Scientific Officer Dennis Williams - Senior Vice President, Late Stage Development John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Matthew Cowper - Leerink Partners Paul Jeng - Guggenheim Securities Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities George Farmer - Scotiabank Arthur He - H.C. Wainwright Kuan-Hung Lin - Wells Fargo Michael Kim - Zacks Small-Cap Research Alexandre Bouilloux - Barclays Operator Good day and welcome to the Adaptimmune Second Quarter 2024 Conference Call.
US FDA approves Adaptimmune's gene therapy for rare type of cancer
The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind gene therapy to treat adult patients with a rare type of cancer that affects soft tissues who have received prior chemotherapy.
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further.
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
By Michael Kim
